Literature DB >> 9575527

Chemotherapy for brain tumors.

I V Pech1, K Peterson, J G Cairncross.   

Abstract

Traditionally, cytotoxic drugs have played a limited role in the treatment of brain tumors, but important advances in chemotherapy have occurred during the past decade. Certain central nervous system (CNS) malignancies are remarkably chemosensitive. These include primary CNS lymphoma, medulloblastoma, oligodendroglioma, and intracranial germ-cell tumors. This review focuses on advances in the chemotherapy of these chemosensitive tumors and also discusses the potential use of chemotherapeutic agents, both cytotoxic and cytostatic, in other brain tumors, such as glioblastomas and anaplastic astrocytomas. In addition, a brief description of future directions that may hold promise, including high-dose chemotherapy with stem-cell rescue, blood-brain barrier disruption, and regional treatment using controlled-release biodegradable polymers, is included.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9575527

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  12 in total

1.  High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease.

Authors:  Howard Mutsando; Magid Fahim; Devinder S Gill; Carmel M Hawley; David W Johnson; Maher K Gandhi; Paula V Marlton; Helen G Mar Fan; Peter N Mollee
Journal:  Am J Blood Res       Date:  2012-01-01

2.  Long-lasting partial regression of glioblastoma multiforme achieved by edotecarin: case report.

Authors:  Eduard Vrdoljak; Marijo Boban; Zana Saratlija-Novaković; Josipa Jović
Journal:  Croat Med J       Date:  2006-04       Impact factor: 1.351

3.  High concentration of Daunorubicin and Daunorubicinol in human malignant astrocytomas after systemic administration of liposomal Daunorubicin.

Authors:  K W Albrecht; P C de Witt Hamer; S Leenstra; P J Bakker; J H Beijnen; D Troost; P Kaaijk; A D Bosch
Journal:  J Neurooncol       Date:  2001-07       Impact factor: 4.130

4.  Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas.

Authors:  K D Geiger; P Stoldt; W Schlote; A Derouiche
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

5.  Tumor vascular leakiness and blood volume estimates in oligodendrogliomas using perfusion CT: an analysis of perfusion parameters helping further characterize genetic subtypes as well as differentiate from astroglial tumors.

Authors:  Jayant Narang; Rajan Jain; Lisa Scarpace; Sona Saksena; Lonni R Schultz; Jack P Rock; Mark Rosenblum; Suresh C Patel; Tom Mikkelsen
Journal:  J Neurooncol       Date:  2010-08-01       Impact factor: 4.130

6.  P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy.

Authors:  Stefan Oberndorfer; Maria Piribauer; Christine Marosi; Heinz Lahrmann; Peter Hitzenberger; Wolfgang Grisold
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.130

7.  Phase II trial of SarCNU in malignant glioma: unexpected pulmonary toxicity with a novel nitrosourea: a phase II trial of the national cancer institute of canada clinical trials group.

Authors:  Marc Webster; Gregory Cairncross; Stan Gertler; James Perry; Nancy Wainman; Elizabeth Eisenhauer
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

8.  Temozolomide as first-line agent in treating high-grade gliomas: phase II study.

Authors:  S Chibbaro; L Benvenuti; A Caprio; S Carnesecchi; F Pulerà; F Faggionato; D Serino; C Galli; M Andreuccetti; N Buxton; R Gagliardi
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

9.  Hypoxanthine transport in human glioblastoma cells and effect on cell susceptibility to methotrexate.

Authors:  Wei Kong; Joanne Wang
Journal:  Pharm Res       Date:  2003-11       Impact factor: 4.200

10.  Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas.

Authors:  Ayman I Omar; Warren P Mason
Journal:  Core Evid       Date:  2010-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.